Compare Inovio Pharmaceuticals Inc (INO) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs PubMatic Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while PubMatic Inc trades at $12.83 (market cap $607.48M). The key difference: PubMatic Inc is far larger — about 6.8× Inovio Pharmaceuticals Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | PUBM | |
|---|---|---|
Market Cap | $89.27M | $607.48M |
Sector | Health | Technology |
52-Week High | $2.87 | $13.83 |
52-Week Low | $1.05 | $6.28 |
Enterprise Value | $60.28M | $504.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
PUBM trades at $13.07, up 2.67% today, with a bullish technical signal from moving averages and oversold RSI conditions. The company reported a net loss of -$14.46M in 2025 despite beating Q1 2026 EPS estimates, with revenue at $282.93M. Recent news highlights product launches like AgenticOS and partnerships expanding its AI-powered ad tech reach, while analyst consensus is evenly split between Buy and Hold.
The outlook is mixed: strong cash flow and innovation in AI advertising support growth potential, but persistent negative margins and high P/E of 132 pose valuation risks. Upside exists if upcoming Q2 2026 earnings beat expectations, though competitive and macroeconomic pressures remain headwinds for profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
